Top Pharmaceutical Companies in Los Angeles, CA (79)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.
Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.
Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as...
Daiichi Sankyo's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate sustained year-over-year revenue increases driven primarily by the oncology franchise, notably ENHERTU and DATROWAY. Management maintains forward revenue growth guidance while highlighting continued indication and geographic expansion for these assets.
Strategic Partnerships: Large, multi‑asset collaborations with AstraZeneca and Merck validate the DXd platform and provide capital, development support, and commercial reach. These alliances underpin scale‑up and reinforce the medium‑term growth outlook in oncology.
Strong Market Position & Advantage: The company is recognized as a leader in oncology antibody‑drug conjugates, with ENHERTU establishing leading shares in key indications and additional approvals broadening use. Category leadership is further supported by expanding first‑line and tumor‑agnostic indications.
Medspas are booming, and are often a path for individual nurses to become business owners. We believe that’s a good thing for them, their communities, local economies, and clients. We unlock the entrepreneurial opportunity in aesthetics for those with the moxie to take the leap. Moxie gives aesthetic entrepreneurs everything they need to successfully compete (and win) against even the biggest...
RDI Trials is a tech-enabled Contract Research Organization (CRO) specializing in In Vitro Diagnostics (IVD) development. They offer end-to-end services, including sourcing samples and managing clinical trials to help IVD manufacturers obtain FDA clearance.
A closed-door pharmacy working to disrupt, shake up, and give the chills to industry giants. We understand that truly changing the way patients access affordable prescriptions must first start with the team behind the counter (so to speak)! The Honeybee family works together to support each other and, in turn, our patients every day to improve pharmacy standards both within...
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to...
Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together,...
Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs.
At Solventum, we enable better, smarter, safer healthcare to improve lives. We never stop solving for you
Solventum's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader or co‑leader in core niches such as negative‑pressure wound therapy and hospital coding/CDI software, with widely deployed platforms and recognized standings. Brand strength and installed bases across MedSurg, Dental, and HIS reinforce competitive positioning.
Resilient & Sustainable Growth: Recent quarters show positive organic sales growth, and guidance points to continued low‑single‑digit expansion. Feedback suggests momentum is supported across key segments, aligning with a steady, incremental trajectory.
Future-Ready Strategy: Management outlines a multi‑year plan centered on portfolio focus, R&D‑led innovation, and selective M&A to accelerate growth. Actions such as SKU rationalization, product launches, and targeted partnerships indicate preparation for longer‑term expansion.
ICU Medical connects patients and caregivers through safe, life-saving, life-enhancing IV therapy systems, software, solutions, and consumables.
Lightship is your complete solution for decentralized clinical trials. We built our virtual-first clinical trial model from the ground up, allowing patients to participate in clinical trials from the comfort of home. Come join the team perfecting the way clinical trials are done!
.jpg)
Obagi Cosmeceuticals is a specialty pharmaceutical company that develops, markets and sells, and is the leading provider of proprietary topical aesthetic and therapeutic clinically-proven skin care systems in the physician-dispensed market. The systems are designed to prevent and improve the most common and visible skin disorders. The foundation of the company began in 1988 with the creation of the Obagi...
Ashfield Advisory is a business unit that provides integrated advisory and consulting services to the healthcare industry, leveraging an ecosystem of specialized businesses for insight, strategy, and action.
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
.png)
Sleuth is a startup that delivers done-for-you competitive intelligence insights and reports to biopharma companies and investors. We use AI agents and a proprietary database of over 100M data points and documents to power bespoke analyses for executives and a range of business-focused teams across the industry. Among our current customers are some of the largest pharma companies in the...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary...
